Tanxitumab combined with lenalidomide has been approved in Taiwan for the treatment of relapsed/refr

Tencetuximab combined with lenalidomide has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma in Taiwan, as announced by Novartis (Shanghai Stock Exchange code: six hundred and eighty-eight thousand four hundred and twenty-eight; Hong Kong Stock Exchange code: nine thousand nine hundred and sixty-nine) today.